Subclinical multisystem neurologic disease in "pure" OPA1 autosomal dominant optic atrophy.

Abstract

Mutations affecting the nuclear gene encoding the mitochondrial OPA1 protein are the commonest causes of autosomal dominant optic atrophy (DOA). More recently OPA1 mutations have been shown to cause a disorder of mitochondrial DNA (mtDNA) maintenance, thus explaining the extraocular features observed in ∼20% of OPA1 mutation carriers with “DOA+,” which include deafness, progressive external ophthalmoplegia (PEO), myopathy, ataxia, neuropathy, and spastic paraplegia.1,2 However, it remains puzzling why, unlike other hereditary mtDNA maintenance disorders (e.g., POLG1 3), most OPA1 mutation carriers only appear to develop isolated optic neuropathy. To determine whether this is actually the case, we looked for electrophysiologic evidence of subclinical multisystem disease in a sample of patients with clinically “pure” DOA. Because spasticity is an unusual clinical finding in mitochondrial disease, we were particularly interested to look for evidence of subclinical corticospinal tract (CST) disease in this clinically asymptomatic group, specifically to gain insight into the role of mitochondrial dysfunction in other more common neurodegenerative motor disorders. ### Methods. Fourteen patients with confirmed pathogenic OPA1 mutations were recruited prospectively: 1) 13 patients with bilateral optic atrophy and no evidence of any neurologic deficit, classified as “pure” DOA; and 2) 1 visually asymptomatic OPA1 mutation carrier (c.1294A>G) with no clinical or electrophysiologic evidence of optic nerve dysfunction. MRI was performed as part of the patients' initial diagnostic workup for their unexplained bilateral optic neuropathy. All patients had nerve conduction studies (NCS), needle EMG, and transcranial magnetic stimulation (TMS) was used to obtain motor evoked potentials …